Attached files

file filename
EX-32.2 - CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 OF CAROLINE M. LOEWY - CORCEPT THERAPEUTICS INCdex322.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A) OF CAROLINE M. LOEWY - CORCEPT THERAPEUTICS INCdex312.htm
EX-32.1 - CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 OF JOSEPH K. BELANOFF, M.D. - CORCEPT THERAPEUTICS INCdex321.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A) OF JOSEPH K. BELANOFF, M.D - CORCEPT THERAPEUTICS INCdex311.htm
EX-10.28 - DEVELOPMENT AGREEMENT - CORCEPT THERAPEUTICS INCdex1028.htm
EX-10.25 - FORM OF OPTION AGREEMENT - CORCEPT THERAPEUTICS INCdex1025.htm
EX-10.29 - MASTER SERVICES AGREEMENT - CORCEPT THERAPEUTICS INCdex1029.htm
10-K - FORM 10-K - CORCEPT THERAPEUTICS INCd10k.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1) Registration Statement (Form S-8 No. 333-116127) pertaining to the 2000 Stock Option Plan and the 2004 Equity Incentive Plan of Corcept Therapeutics Incorporated,

(2) Registration Statements (Form S-8 Nos. 333-150199, 333-158406 and 333-164531) pertaining to the 2004 Equity Incentive Plan of Corcept Therapeutics Incorporated, and

(3) Registration Statements (Form S-3 Nos. 333-149087, 333-150204, 333-163140, 333-167211, 333-168928, 333-141881, 333-150232 and 333-150259) of Corcept Therapeutics Incorporated and in the related Prospectuses;

of our reports dated March 15, 2011, with respect to the financial statements of Corcept Therapeutics Incorporated (a development stage company) and the effectiveness of internal control over financial reporting of Corcept Therapeutics Incorporated included in this Annual Report (Form 10-K) of Corcept Therapeutics Incorporated for the year ended December 31, 2010.

/s/ Ernst & Young LLP

Palo Alto, California

March 15, 2011